Journal: Cancers
Article Title: A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness
doi: 10.3390/cancers15245773
Figure Lengend Snippet: ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.
Article Snippet: To this end, we utilized immunohistochemistry with custom-made VisioPharm (Version 2018.4) analysis apps to determine the percent of total tumor area with immunoreactivity to CD68, CD3, CD4, CD8a, neutrophil elastase, and CD45r.
Techniques: Expressing, Immunohistochemistry, Software, MANN-WHITNEY